

LKY-047 biochemical

LKY-047

CATALOG #
AAA228005


PRODUCT SYNONYMS

LKY-047; LKY-047 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1954681-29-8
Targets&IC50	CYP2J2:1.7 uM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	LKY-047 is a strong competitive inhibitor of CYP2J2-mediated astemizole O-demethylase and terfenadine hydroxylase activity, with K_i values of 0.96 uM and 2.61 uM, respectively. LKY-047 also acted as an uncompetitive inhibitor of CYP2J2-mediated ebastine hydroxylation with a K_i value of 3.61 uM[1]. At 20 uM LKY-047 concentration, approximately 20-fold greater than the K_i value, LKY-047 is found to inhibit CYP2J2 by 85.3%, and only slightly affecting the enzyme activities of the other P450s tested. LKY-047 weakly inhibits CYP2D6 enzyme activity (37.2%) at 20 uM concentration[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Benzyl-PEG7-THP, CAS 230620-75-4



Structure
Benzyl-PEG7-THP, CAS 230620-75-4

ADDITIONAL INFORMATION

Related Product Information for LKY-047 biochemical	LKY-047, a Decursin derivative, is a potent and selective reversible competitive cytochrome P4502J2 (CYP2J2) inhibitor with an IC ₅₀ of 1.7 uM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A.
References	1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://www.aaabiotech.com/biochemical/lky-047/228005>